Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico (Q28280394)

1

0 references

Charles D Ericsson

2

0 references

Zhi-Dong Jiang

3

0 references

Pablo C Okhuysen

4

0 references

Juan H M Meléndez Romero

5

0 references

Norma Hernandez

6

0 references

William P Forbes

7

0 references

Audrey Shaw

8

0 references

Enoch Bortey

9

0 references

language of work or name

English

0 references

publication date

2010

1 reference

Journal of Travel Medicine

PubMed

published in

0 references

volume

17

0 references

issue

2

0 references

page(s)

111-7

0 references

cites work

New insights and directions in travelers' diarrhea

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Systematic review: the epidemiology and clinical features of travellers' diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Natural history of enteroaggregative and enterotoxigenic Escherichia coli infection among US travelers to Guadalajara, Mexico.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Travelers' diarrhea: modern concepts and new developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Epidemiology of traveler's diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

The role of psychological and biological factors in postinfective gut dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Prognosis in post-infective irritable bowel syndrome: a six year follow up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Gastrointestinal symptoms after infectious diarrhea: a five-year follow-up in a Swedish cohort of adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Current and future developments in travelers' diarrhea therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Therapy of travelers' diarrhea with rifaximin on various continents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Epidemiology, etiology and pathophysiology of traveler's diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Results of a double-blind placebo-controlled study using ciprofloxacin for prevention of travelers' diarrhea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Prevention of travelers' diarrhea by the tablet formulation of bismuth subsalicylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Travelers' diarrhea: antimicrobial therapy and chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Lack of emergence of resistant fecal flora during successful prophylaxis of traveler's diarrhea with norfloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Prevention and treatment of traveler's diarrhea. Focus on antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Expert review of the evidence base for self-therapy of travelers' diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X

Expert review of the evidence base for prevention of travelers' diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2009.00385.X